BOD with teeth
Having Scott on the BOD makes perfect sense to me. He owns a third of the company's O/S. With that much skin in the game, he has a major interest in the company's success. Management should feel the pressure to get the EU distribution deal signed for Lymphoseek, and complete the Phase 3 FDA trials.
Looking forward to some newsworthy progress by Jed.